Abstract

Biological function of proteins is frequently associated with the formation of complexes with small-molecule ligands. Experimental structure determination of such complexes at atomic resolution, however, can be time-consuming and costly. Computational methods for structure prediction of protein/ligand complexes, particularly docking, are as yet restricted by their limited consideration of receptor flexibility, rendering them not applicable for predicting protein/ligand complexes if large conformational changes of the receptor upon ligand binding are involved. Accurate receptor models in the ligand-bound state (holo structures), however, are a prerequisite for successful structure-based drug design. Hence, if only an unbound (apo) structure is available distinct from the ligand-bound conformation, structure-based drug design is severely limited. We present a method to predict the structure of protein/ligand complexes based solely on the apo structure, the ligand and the radius of gyration of the holo structure. The method is applied to ten cases in which proteins undergo structural rearrangements of up to 7.1 Å backbone RMSD upon ligand binding. In all cases, receptor models within 1.6 Å backbone RMSD to the target were predicted and close-to-native ligand binding poses were obtained for 8 of 10 cases in the top-ranked complex models. A protocol is presented that is expected to enable structure modeling of protein/ligand complexes and structure-based drug design for cases where crystal structures of ligand-bound conformations are not available.

Highlights

  • Interactions between proteins and small molecules are involved in many biochemical phenomena

  • The proteins used in this study undergo large conformational changes upon ligand binding

  • After the refinement cycles we find a good correlation between the radius of gyration and the root mean square deviations (RMSD) to the holo structures

Read more

Summary

Introduction

Interactions between proteins and small molecules are involved in many biochemical phenomena. Insight into these processes relies on detailed knowledge about the structure of protein/ligand complexes, e.g. how enzymes stabilize substrates and cofactors in close proximity. Almost all drugs are small-molecule ligands that interact with enzymes, receptors or channels. Ligand-bound receptor complex structures are a critical prerequisite for understanding biological function and for structure based drug design. Structure determination of protein/ligand-complexes can be difficult, time-consuming and expensive. Conformational transitions of the receptor associated with ligand binding pose a severe challenge to the structure elucidation of holo complexes [5,6,7,8]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call